UMIN-CTR History

Name：　　UMIN ID：


Unique ID issued by UMIN UMIN000021311
Receipt number R000022107
Scientific Title phase 2 study of the combination therapy, docetaxel and trastuzumab, for advanced extramammary Paget's disease.
Date of disclosure of the study information 2016/03/03
Last modified on 2023/11/16 14:56:30

No. Disposal Last modified on Item of update
1 Insert 2016/03/03 14:46:24
2 Update 2016/03/11 19:50:30 Interventions/Control_1
Interventions/Control_1
3 Update 2016/03/11 19:53:03 Primary outcomes
Primary outcomes
Key secondary outcomes
Key secondary outcomes
4 Update 2017/01/26 18:41:21 Public title
Acronym
5 Update 2017/01/26 18:43:03 Key secondary outcomes
Key secondary outcomes
6 Update 2017/01/26 19:21:50


Key inclusion criteria
Key inclusion criteria
Key exclusion criteria
Key exclusion criteria
Target sample size
7 Update 2017/01/26 19:25:29 Name of primary person or sponsor
Organization
Name of secondary funder(s)
Name of secondary funder(s)
Research ethics review
8 Update 2017/01/26 19:26:16 Date of protocol fixation
Anticipated trial start date
9 Update 2017/03/14 20:42:58 Recruitment status
10 Update 2017/06/12 22:41:45 Recruitment status
11 Update 2017/06/12 22:46:01 Organization
Organization
Organization
Category of Funding Organization
Name of secondary funder(s)
Name of secondary funder(s)
12 Update 2019/12/16 20:03:28 Recruitment status
Date of IRB
Last follow-up date
13 Update 2019/12/16 20:03:55 Number of participants that the trial has enrolled
14 Update 2019/12/16 20:07:51 1st name of lead principal investigator
Last name of lead principal investigator
1st name of lead principal investigator
Last name of lead principal investigator
Zip code

Last name of contact person

Last name of contact person
Zip code
Organization
Organization
Address
Address
Tel
Email
Secondary IDs
Study ID_1
Org. issuing International ID_1
Org. issuing International ID_1
15 Update 2023/11/16 14:56:30 Recruitment status